Polymers News and Research

RSS

Scientists improve methods for flavanol antioxidant determination in cocoa, chocolate

Two scientific publications report on improved methods for determining the amounts of flavanol antioxidants in cocoa and chocolate. The research, sponsored by The Hershey Center for Health and Nutrition, was a collaboration between scientists at The Hershey Company and other scientific laboratories.

15 Feb 2011

NIST team demonstrates a method for controlling different-sized nanoparticle production

The same properties that make engineered nanoparticles attractive for numerous applications-small as a virus, biologically and environmentally stabile, and water-soluble-also cause concern about their long-term impacts on environmental health and safety.

3 Feb 2011

Detergent manufacturers in search for phosphate-free formulas

Phosphate-free automatic dishwashing detergents - introduced to combat the phosphate-fed algae blooms that foul the nation's lakes and rivers - may be making the fish happy. But they're putting a frown on the faces of some consumers who say the new products leave dishes dirty. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

28 Jan 2011

Biotage announces release of new Analytical Sample Preparation Catalog

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced the release of its new Analytical Sample Preparation Catalog. The expanded, 200-page catalog includes a range of products for Bioanalytical, Forensic, Clinical, Environmental, Agrochemical and Food Applications.

27 Jan 2011

Prions responsible for BSE can survive in new host environment

Scientists from the Florida campus of The Scripps Research Institute have shown that prions, bits of infectious protein that can cause fatal neurodegenerative disease such as bovine spongiform encephalopathy or "mad cow disease," have the ability to adapt to survive in a new host environment.

17 Dec 2010

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.

15 Dec 2010

Shrink, EV Group enter development agreement for StemDisc stem cell and cell culturing platform

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into a multi-year development and manufacturing agreement with EV Group, a 30 year old Austria-based leader in the nano-imprint lithography process designing and equipment manufacturing.

8 Dec 2010

Conference focuses on new molecular, mechanical solutions to improve surgeries

A two-day conference at the University of Chicago Medical Center is designed to offer surgeons a peek at the profession's future by focusing on new molecular and mechanical solutions to three age-old problems: preventing the breakdown of anastomoses (the surgically created connections between blood vessels), improving tissue healing after surgery and developing new tools to test and sharpen surgical skills.

4 Dec 2010

Research on ribosome could aid antibiotic development against MRSA infection

Theoretical biologists at Los Alamos National Laboratory have used a New Mexico supercomputer to aid an international research team in untangling another mystery related to ribosomes-those enigmatic jumbles of molecules that are the protein factories of living cells.

3 Dec 2010

MiMedx awarded QTDP grant for CollaFix drug delivery device

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has been awarded a Qualifying Therapeutic Discovery Project grant (QTDP) from the U.S. Government. The grant, in the amount of $244,479, has been made to defer some of the Company's research expenditures related to the development of its novel and patented technology, CollaFix™, as a drug delivery device.

2 Dec 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

Spray-on organic/inorganic films

Coatings functionalize surfaces or protect them from processes such as corrosion, abrasion, and weathering, and may provide an aesthetic appearance—automotive coatings and non-stick frying pans are good examples. Contact lenses, implants, LEDs, or photovoltaic cells require extremely thin coatings. In the journal Angewandte Chemie, the teams led by Gero Decher at the Institut Charles Sadron in Strasbourg (France) have now introduced a new process for the production of ultrathin coatings that is especially simple, versatile, and suitable for large-scale processes.

24 Nov 2010

SESAME Stent effective for patients undergoing angioplasty of SVG

A new study revealed that the novel self-expanding super-elastic all-metal endoprosthesis stent (SESAME Stent) used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions has 100% acute success, low 30 day major adverse cardiac events (MACE) rates, and 9-month patency comparable to balloon expandable stents without embolic protection.

17 Nov 2010

UC San Diego researchers receive NIH grant to develop scaffolds

University of California, San Diego NanoEngineers won a grant from the National Institutes of Health (NIH) to develop the tools to manufacture biodegradable frames around which heart tissues functional blood vessels included will grow.

16 Nov 2010

CMU receives $2.9 million DOD research grant to develop therapy for amputees

CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.

8 Nov 2010

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

4 Nov 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Nitric oxide inhalation reduces pain in sickle cell disease patients

Inhaling nitric oxide appears to safely and effectively reduce pain crises in adults with sickle cell disease, researchers report.

20 Oct 2010

Particle Sciences enters licensing, technology agreement with Solubest

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement. Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.

20 Oct 2010